Vnitřní lékařství 3/2020

HLAVNÍ TÉMA Prodlužování agresivní antitrombotické léčby po infarktu myokardu: proč, komu a jakou léčbu vybrat? 168 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2020; 66(3): 160–168 /  www.casopisvnitrnilekarstvi.cz 3. Varenhorst C, Hasvold P, Johansson S. Culprit and nonculprit recurrent ischemic events in patients with myocardial Infarction: Data from SWEDEHEART. J Am Heart Assoc 2018;7: e007174. DOI: 10.1161.JAHA.117.007174. 4. Nakatani D, Sakata Y, Suna S. Incidence, predictors, and subsequent mortality risk of re‑ current myocardial infarction in patients following discharge for acute myocardial infar‑ ction. Circ J 2013; 77: 439–446. 5. Bhatt DL, Fox KA, Hacke W. Clopidogrel and aspirin versus aspirin alone for the preven‑ tion of atherothrombotic events. N Engl J Med 2006; 354: 1706–1717. 6. Bhatt DL, Flather MD, Hacke W. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982-8. 7. Roe MT, Armstrong PW, Fox KA. Prasugrel versus clopidogrel for acute coronary syndro‑ mes without revascularization. N Engl J Med 2012; 367: 1297–1309. 8. Bonaca MP, Bhatt DL, Cohen M. Long‑term use of ticagrelor in patients with prior myo‑ cardial infarction. N Engl J Med 2015; 372: 1791–1800. 9. Bonaca MP, Bhatt DL, Steg PG. Ischaemic risk a efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS‑TIMI 54. Eur Heart J 2016; 37: 1133–1142. 10. Dellborg M, Bonaca MP, Storey RF. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS‑TIMI 54. Eur Heart J 2017; 38(suppl): 794–795. 11. Magnani G, Storey RF, Steg PG. Efficacy and safety of ticagrelor for long‑term secon‑ dary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS‑TIMI 54 trial. Eur Heart J 2016; 37: 400–408. 12. Bonaca MP, Bhatt DL, Storey RF. Ticagrelor in prevention of ischemic events after myocar‑ dial infarction in patients with peripheral artery disease. J Am Coll Cardiol 2016; 67: 719–728. 13. Valgimigli M, Bueno H, Byrne RA. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018; 39: 213–254. 14. Neumann FJ, Sousa‑Uva M, Ahlsson A. 2018 ESC.EACTS guidelines on myocardial revas‑ cularization. Eurointervention 2019; 14: 1435–1534. 15. Hurlen M, Abdelnoor M, Smith P. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347: 969–974. 16. Rothberg MB, Celestin C, Fiore LD. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta‑analysis with estimates of risk and benefit. Ann In‑ tern Med 2005; 143: 241–250. 17. Oldgren J, Budaj A, Granger CB. Dabigatran vs placebo in patients with acute corona‑ ry syndromes on dual antiplatelet therapy: a randomized, double‑blind, phase II trial. Eur Heart J 2011; 32: 2781–2789. 18. Alexander JH, Lopes RD, James S. Apixaban with antiplatelet therapy after acute co‑ ronary syndrome. N Engl J Med 2011; 365: 699–708. 19. Mega JL, Braunwald E, Wiviott SD. Rivaroxaban in patients with a recent acute coro‑ nary syndrome. N Engl J Med 2012; 366: 9–19. 20. Connolly SJ, Eikelboom JW, Bosch J. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double‑blind, placebo­ ‑controlled trial. Lancet 2018; 391: 205–218. 21. The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and ma‑ nagement of chronic coronary syndromes. Eur Heart J 2019; doi:10.1093.eurheartj.ehz425. Nenechte si ujít aktuální informace o možnostech vzdělávání lékařů, lékárníků a dalších odborníků ve zdravotnictví SLEDUJTE NÁS NA SOCIÁLNÍCH SÍTÍCH https://www.facebook.com/ SolenMedicalEducation/ @SolenMedicalEducation https://twitter.com/ MedicalSolen @MedicalSolen